Vestal Point Capital, LP
About Vestal Point Capital, LP’s 13F portfolio
Vestal Point Capital, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Vestal Point Capital, LP reported $4.3B across 68 US-listed positions (). Its largest position is BioMarin Pharmaceutical Inc (BMRN) at 8.1% of the reported book, and its ten biggest holdings make up 50% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: BMRN BioMarin Pharmaceutical Inc | — — | 8.1% | 6.0M | $344.8M |
| 2 | NASDAQ: NBIX Neurocrine Biosciences Inc | — — | 7.4% | 1.9M | $316.8M |
| 3 | NASDAQ: ABVX Abivax SA | — — | 7.3% | 2.3M | $313.1M |
| 4 | NASDAQ: UTHR United Therapeutics Corp | — — | 5.5% | 435K | $235.7M |
| 5 | NASDAQ: ELVN Enliven Therapeutics Inc | — — | 4.7% | 4.0M | $203.0M |
| 6 | NASDAQ: NRIX Nurix Therapeutics Inc | — — | 4.6% | 8.1M | $195.3M |
| 7 | NASDAQ: BCAX Bicara Therapeutics Inc | — — | 3.6% | 5.3M | $155.9M |
| 8 | NASDAQ: TSHA Taysha Gene Therapies Inc | — — | 3.1% | 19.4M | $132.2M |
| 9 | NASDAQ: ARWR Arrowhead Pharmaceuticals Inc | — — | 3.0% | 1.6M | $128.4M |
| 10 | NYSE: ABT Abbott Laboratories | — — | 3.0% | 1.4M | $127.0M |
| 11 | NYSE: ZBH Zimmer Biomet Holdings Inc | — — | 2.8% | 1.4M | $120.5M |
| 12 | NASDAQ: IRON Disc Medicine Inc | — — | 2.6% | 1.6M | $113.4M |
| 13 | NASDAQ: GLUE Monte Rosa Therapeutics Inc | — — | 2.6% | 4.6M | $111.3M |
| 14 | NASDAQ: PODD Insulet Corp | — — | 2.4% | 670K | $102.0M |
| 15 | NASDAQ: ASND Ascendis Pharma A/S | — — | 2.3% | 375K | $100.0M |
| 16 | NASDAQ: AZN AstraZeneca PLC | — — | 2.0% | 450K | $85.3M |
| 17 | NASDAQ: SNY Sanofi SA | — — | 2.0% | 2.0M | $85.3M |
| 18 | NASDAQ: RVMD Revolution Medicines Inc | — — | 2.0% | 450K | $84.3M |
| 19 | NASDAQ: BCRX BioCryst Pharmaceuticals Inc | — — | 1.9% | 8.3M | $83.0M |
| 20 | NASDAQ: DYN Dyne Therapeutics Inc | — — | 1.8% | 3.4M | $75.0M |
| 21 | NASDAQ: NKTR Nektar Therapeutics | — — | 1.6% | 1.0M | $69.8M |
| 22 | NYSE: GMED Globus Medical Inc | — — | 1.6% | 850K | $67.2M |
| 23 | NASDAQ: TARS Tarsus Pharmaceuticals Inc | — — | 1.5% | 1.1M | $66.1M |
| 24 | NASDAQ: IMTX Immatics NV | — — | 1.5% | 6.2M | $62.6M |
| 25 | NASDAQ: TRVI Trevi Therapeutics Inc | — — | 1.4% | 3.1M | $57.8M |
Showing 1–25 of 68 positions on this page reported in this 13F.
- Healthcare99%
- AddedBMRNBioMarin Pharmaceutical Inc+68.5%$344.8M
- AddedNBIXNeurocrine Biosciences Inc+50.4%$316.8M
- AddedABVXAbivax SA+56.6%$313.1M
- AddedUTHRUnited Therapeutics Corp+480%$235.7M
- AddedELVNEnliven Therapeutics Inc+23.1%$203.0M
- AddedNRIXNurix Therapeutics Inc+23.8%$195.3M
- AddedTSHATaysha Gene Therapies Inc+7.9%$132.2M
- NewABTAbbott Laboratories—$127.0M
- AddedZBHZimmer Biomet Holdings Inc+637%$120.5M
- AddedIRONDisc Medicine Inc+121%$113.4M
- ReducedBCAXBicara Therapeutics Inc−3.2%$155.9M
- ReducedARWRArrowhead Pharmaceuticals Inc−30.8%$128.4M
- ReducedRVMDRevolution Medicines Inc−81.1%$84.3M
- ReducedDYNDyne Therapeutics Inc−15.6%$75.0M
- ReducedIMCRImmunocore Holdings PLC−34.9%$57.1M
- ReducedRGENRepligen Corp−56.8%$54.6M
- ReducedBMYBristol-Myers Squibb Co−20.0%$46.1M
- ReducedALCAlcon AG−37.5%$33.5M
- ReducedRAPPRapport Therapeutics Inc−49.2%$30.4M
- ReducedVKTXViking Therapeutics Inc−25.6%$26.5M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | TENX TENAX THERAPEUTICS, INC. | 13G | 9.9% | 2.5M | Filed 14 NOV 2025 |
| 2 | BCAX Bicara Therapeutics Inc. | 13G | 8.3% · 2 classes | 5.4M | Filed 15 MAY 2026 |
| 3 | ANRO Alto Neuroscience, Inc. | 13G | 8.0% | 2.5M | Filed 17 FEB 2026 |
Showing all 3 disclosed stakes.
Reading Vestal Point Capital, LP’s 13F portfolio
Vestal Point Capital, LP’s $4.3B 13F book is spread across 68 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 50%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are BMRN, NBIX, ABVX, UTHR and ELVN, led by BioMarin Pharmaceutical Inc (BMRN) at 8.1% of the portfolio. The heaviest sector exposure is Healthcare (99%).
What Vestal Point Capital, LP changed last quarter
Between 2026-03-31 and Q2 2026, Vestal Point Capital, LP was a net seller: it opened 11 new positions and added to 31 more, while trimming 21 and closing 33 outright. Against a 68-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was BioMarin Pharmaceutical Inc (BMRN), and its biggest reduction was Bicara Therapeutics Inc (BCAX).
What a 13F does and doesn’t reveal
A 13F captures only Vestal Point Capital, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Vestal Point Capital, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Vestal Point Capital, LP's profile on this page is built directly from those filings.
How current is the 13F data on Vestal Point Capital, LP's page?
It reflects Vestal Point Capital, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Vestal Point Capital, LP files its next quarterly report, this page refreshes automatically.
Can I see Vestal Point Capital, LP's complete list of holdings?
This page highlights Vestal Point Capital, LP's largest positions rather than all 68 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Vestal Point Capital, LP's filings.
Does a 13F show everything Vestal Point Capital, LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Vestal Point Capital, LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Vestal Point Capital, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

